Navigation Links
GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports
Date:7/24/2014

New York, New York (PRWEB) July 24, 2014

The federal judge overseeing thousands of GranuFlo lawsuits (http://www.injurybeacon.com/granuflo-dialysis/lawsuit/) in the U.S. District Court, District of Massachusetts, has issued a qualified protective order for plaintiff medical information covered by the federal Health Insurance Portability and Accountability Act. According to the July 16th Order, U.S. District Judge Douglas P. Woodlock has granted attorneys for Fresenius Medical Care the right to receive HIPAA- protected information. However, neither defense counsel nor their staff may discuss such information with plaintiffs’ treating physicians, and they may only disclose the information in accordance with case management orders. Finally, the Order stipulates that any health information must be returned or destroyed once the GranuFlo recall litigation concludes. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

“Our Firm is representing a number of GanuFlo lawsuit plaintiffs in this proceeding, and we have been monitoring this matter closely,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free GranuFlo lawsuit evaluations to dialysis patients who allegedly suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects within 72 hours of a dialysis treatment involving the use of GranuFlo or NaturaLyte dialysis drugs.

GranuFlo Recall Litigation
Court documents indicate that more than 1,940 lawsuits have been filed in the District of Massachusetts on behalf of dialysis patients who allegedly experienced serious cardiovascular events due to the administration of GranuFlo and NaturaLyte dialysis concentrates. All of the lawsuits pending in the federal litigation similarly allege that Fresenius failed to provide adequate warnings regarding the risks associated with GranuFlo and NaturaLyte, and that the company continued to aggressively market the products even once it became aware of those risks.

Both GranuFlo and NaturaLyte are manufactured by Fresenius Medical Care, and are administered to kidney failure patients to remove toxins from the blood during dialysis treatments. In March 2012, Fresenius issued an Urgent Product Notification for both products that warned of dosage issues that could cause dialysis patients to suffer serious and catastrophic heart side effects. The U.S. Food & Drug Administration (FDA) ultimately granted Class I recall status to the Urgent Product Notification, which indicates GranuFlo and NaturaLyte posed a risk of serious injury and death.

In addition to the cases pending in the District of Massachusetts, additional GranuFlo and NaturaLyte lawsuits have been consolidated on the state level in the Massachusetts’ Middlesex County Superior Court. Filings indicate that more than 3,900 claims are pending in that proceeding. (In re: Consolidated Fresenius Cases, No. MICV2013-03400-O).

Individuals who were allegedly harmed by GranuFlo or NaturaLyte may be entitled to file their own GranuFlo lawsuit. To learn more about filing a GranuFlo recall claim, please visit Bernstein Liebhard LLP’s website, or the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For additional information, and to arrange for a free case review, please call 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.injurybeacon.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/granuflo-lawsuit/granuflo-recall/prweb12045933.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. GranuFlo Lawsuit Consolidation Supported by Fresenius Medical Care, Bernstein Liebhard LLP Reports
2. GranuFlo Recall Website Launched By Hissey Kientz, LLP Law Firm
3. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
4. GranuFlo Lawsuits Filed in Wake of GranuFlo and NaturaLyte Recall Mount in State and Federal Courts, Bernstein Liebhard LLP Reports
5. The National Plaintiff’s Law Firm of Baron and Budd Handling Granuflo Recall Lawsuits
6. New Granuflo Cardiac Arrest Lawsuit: Now, AttorneyOne Can Provide Advice
7. GranuFlo Lawsuit News: Bernstein Liebhard LLP Reports on Growing Litigation Surrounding GranuFlo Recall
8. Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama
9. GranuFlo Lawsuits Moving Forward in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports
10. GranuFlo Lawsuits Move Forward, as Bernstein Liebhard Notes Issuance of New Order in Federal GranuFlo Recall Litigation
11. GranuFlo Lawsuit News: W.Va. Man’s Lawsuit Goes to Federal Court, Rottenstein Law Group LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Northern Kentucky - Cincinnati, Ohio (PRWEB) , ... ... ... leader in the production of miniature, folded, pharmaceutical inserts and outserts. As ... & Serialization Device. This addition will enable Flottman to individually code professional ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... celebrated its 10th anniversary with the grand opening of the Sober College Robert ... event spanned two days, December 2-3, and was attended by an overwhelming amount ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical Center ... NY, on December 3rd, to benefit Holy Name Medical Center's programs and services. ... raised over $1 million - the largest event in the Center's history, both ...
(Date:12/9/2016)... ... 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) ... summer of 2016. The program was made possible by a Pennsylvania Department of ... Health and Human Services Administration. The broadcast, Use Your Head: Properly Managing ...
(Date:12/8/2016)... ... 2016 , ... After enjoying record-breaking attendance at its last ... 33rd Annual Issues & Research Conference, March 2-3, 2017, at the Westin ... is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." 2016 ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Research and Markets has announced the addition of ... report to their offering. ... The report also analyses the market by the following Technology Types: Label-Free ... the US, Canada , Japan , ... Latin America , and Rest of World. Annual ...
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company ... severe, rare diseases, today announced that senior management will participate in ... Conference at the InterContinental Barclay Hotel in New York ... ET. About aTyr Pharma ... aTyr Pharma is engaged in the ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, Inc. ... (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to ... for the treatment of bacterial infections including those ... recognized as an attractive antibacterial target for more ... of suitable chemical starting points has hampered its ...
Breaking Medicine Technology: